Dr. Angel Goenawan, MD

Dr. Goenawan practices at The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts.

Dr. Goenawan's NPI, 1710448949, was assigned on March 29, 2019. Dr. Goenawan holds Delaware license C1-0025080.

Dr. Goenawan's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD, at 148 Chestnut St, Needham, MA 02492.

Dr. Goenawan's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts. Dr. Goenawan is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Goenawan to 4 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goenawan practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Goenawan's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Goenawan is licensed in Delaware.

CMS data shows 1,048 Medicare services from Dr. Goenawan across 6 procedure codes in 2024, for 368 Medicare patients. Medicare paid $81,847 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 368 Medicare patients who saw Dr. Goenawan in 2024. The largest group is 75 to 84, with 143 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goenawan's median patient age at 76, with 51% women.

In 2024, Dr. Goenawan wrote 386 Medicare Part D claims for 151 patients. 84% of them were for generic drugs. CMS names the drug for 114 of them, across 7 drugs with 11 or more claims each, at $537 in total drug cost. In 2023, CMS named 145 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Goenawan for performance year 2024, reported as part of a group. Dr. Goenawan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 4 general payments to Dr. Goenawan from 3 drug and device companies from 2022 to 2024. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $34.